Recon: FDA identifies four deaths in Newron schizophrenia drug trials; Dutch court blocks subcutaneous Keytruda in eight Europea...

08 Oct 2026 Experts weigh in on FDA’s transparency roadmap The US Food and Drug Administration (FDA) recently released a transparency roadmap outlining its achievements in FY 2026 and its priorities for FY 2027. Two key priorities for the future include a proposal to require public disclosure of new drug applications (NDAs) and biologics license applications (BLAs) upon filing, as well as proactively publishing all inspection reports. Regulatory News